New Delhi: Days after a study by the Indian Council of Medical Research supporting mix of Covaxin and Covishield, two major Covid-19 vaccines in India, the Drug Controller General of India has approved a separate study on this mix.
The study as well as the clinical trials of mix use of Covaxin and Covishield will be conducted at Christian Medical College in Vellore in Tamil Nadu.
“Permission has been granted for a research study by CMC Vellore (Tamil Nadu) on mixing of vaccines doses,” Dr VK Paul, NITI Aayog Member (Health), said during a press briefing on Tuesday.
The study had been recommended by a subject expert committee of the Central Drugs Standard Control Organization (CDSCO) on July 29.
This will be different from the study conducted by the ICMR.
The ICMR study had said that administering a mix of Covaxin and Covishield could have better results than administering both doses of the same vaccine.
According to the study, administering a vaccine with adenovirus vector platform base and then following it up with an inactivated whole virus vaccine elicited better immunogenicity.
The combination was also found to be safe, the ICMR study stated.
The study was titled ‘Serendipitous Covid-19 Vaccine-Mix in Uttar Pradesh, India: Safety and Immunogenicity assessment of a heterologous regime’.
However, the sample size was just 18 and ICMR had advised detailed study in the area.
To read the latest news in Gujarati click here